This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed/refractory autoimmune inflammatory diseases (AID).
Age ≥ 18 years (including the cut - off value), with no restrictions on gender.
Expected survival time ≥ 3 months.
Subjects with relapsed/refractory autoimmune diseases who have failed standard treatment or lack effective treatment options, including but not limited to rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, idiopathic inflammatory myopathies, Sjögren's syndrome, connective tissue disease - related interstitial lung disease, immune thrombocytopenia, primary biliary cholangitis, etc.
Liver and kidney functions and cardiopulmonary functions meet the requirements.
Malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years before screening.
Subjects with positive virus and/or syphilis tests.
Presence of severe heart disease or unstable systemic diseases.